» Articles » PMID: 36973957

Non-eosinophilic Asthma in Nonsteroidal Anti-inflammatory Drug Exacerbated Respiratory Disease

Overview
Publisher Wiley
Date 2023 Mar 28
PMID 36973957
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The cellular inflammatory pattern of nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) is heterogeneous. However, data on the heterogeneity of non-eosinophilic asthma (NEA) with aspirin hypersensitivity are scanty. By examination of N-ERD patients based on clinical data and eicosanoid biomarkers we aimed to identify NEA endotypes potentially guiding clinical management.

Methods: Induced sputum was collected from patients with N-ERD. Sixty six patients (49.6% of 133 N-ERD) with NEA were included in the hierarchical cluster analysis based on clinical and laboratory data. The quality of clustering was evaluated using internal cluster validation with different indices and a practical decision tree was proposed to simplify stratification of patients.

Results: The most frequent NEA pattern was paucigranulocytic (PGA; 75.8%), remaining was neutrophilic asthma (NA; 24.2%). Four clusters were identified. Cluster #3 included the highest number of NEA patients (37.9%) with severe asthma and PGA pattern (96.0%). Cluster #1 (24.2%) included severe only asthma, with a higher prevalence of NA (50%). Cluster #2 (25.8%) comprised well-controlled mild or severe asthma (PGA; 76.5%). Cluster #4 contained only 12.1% patients with well-controlled moderate asthma (PGA; 62.5%). Sputum prostaglandin D levels distinguished cluster #1 from the remaining clusters with an area under the curve of 0.94.

Conclusions: Among identified four NEA subtypes, clusters #3 and #1 represented N-ERD patients with severe asthma but a different inflammatory signatures. All the clusters were discriminated by sputum PGD levels, asthma severity, and age of patients. The heterogeneity of non-eosinophilic N-ERD suggests a need for novel targeted interventions.

Citing Articles

Unique effect of aspirin on local 15-oxo-eicosatetraenoic acid synthesis in asthma patients with aspirin hypersensitivity.

Szatkowski P, Gielicz A, Stepien A, Hartwich P, Kacorzyk R, Plutecka H Clin Transl Allergy. 2024; 14(12):e70004.

PMID: 39722441 PMC: 11669626. DOI: 10.1002/clt2.70004.


Low Prostaglandin E but High Prostaglandin D, a Paradoxical Dissociation in Arachidonic Acid Metabolism in Aspirin-Exacerbated Airway Disease: Role of Airway Epithelium.

Picado C, Machado-Carvalho L, Roca-Ferrer J J Clin Med. 2024; 13(23).

PMID: 39685875 PMC: 11642301. DOI: 10.3390/jcm13237416.


Aspirin hypersensitivity diagnostic index (AHDI): In vitro test for diagnosing of N-ERD based on urinary 15-oxo-ETE and LTE excretion.

Mastalerz L, Trad G, Szatkowski P, Cmiel A, Gielicz A, Kacorzyk R Allergy. 2024; 80(2):534-544.

PMID: 39180224 PMC: 11804310. DOI: 10.1111/all.16281.


Non-eosinophilic asthma in nonsteroidal anti-inflammatory drug exacerbated respiratory disease.

Mastalerz L, Celejewska-Wojcik N, Cmiel A, Wojcik K, Szaleniec J, Hydzik-Sobocinska K Clin Transl Allergy. 2023; 13(3):e12235.

PMID: 36973957 PMC: 10009799. DOI: 10.1002/clt2.12235.

References
1.
Liu J, Wang Y, Johnson M, Li A, Shen W, Wang X . Optimization of phenylacetic acid derivatives for balanced CRTH2 and DP dual antagonists. Bioorg Med Chem Lett. 2012; 22(4):1686-9. DOI: 10.1016/j.bmcl.2011.12.107. View

2.
Laidlaw T, Kidder M, Bhattacharyya N, Xing W, Shen S, Milne G . Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012; 119(16):3790-8. PMC: 3335383. DOI: 10.1182/blood-2011-10-384826. View

3.
Stevens W, Ocampo C, Berdnikovs S, Sakashita M, Mahdavinia M, Suh L . Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease. Am J Respir Crit Care Med. 2015; 192(6):682-94. PMC: 4595675. DOI: 10.1164/rccm.201412-2278OC. View

4.
Olgac M, Guler S, Demir S, Unal D, Ertek B, Ozseker Z . Paucigranulocytic asthma: Do sputum macrophages matter?. Allergy Asthma Proc. 2021; 42(6):530-536. DOI: 10.2500/aap.2021.42.210060. View

5.
Mastalerz L, Celejewska-Wojcik N, Wojcik K, Gielicz A, Cmiel A, Ignacak M . Induced sputum supernatant bioactive lipid mediators can identify subtypes of asthma. Clin Exp Allergy. 2015; 45(12):1779-89. DOI: 10.1111/cea.12654. View